Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

被引：11

作者：

Benza, Raymond L. ^{[1
]}

Langleben, David ^{[2
]}

Hemnes, Anna R. ^{[3
]}

Noordegraaf, Anton Vonk ^{[4
]}

Rosenkranz, Stephan ^{[5
]}

Thenappan, Thenappan ^{[6
]}

Hassoun, Paul M. ^{[7
]}

Preston, Ioana R. ^{[8
]}

Ghio, Stefano ^{[9
]}

Badagliacca, Roberto ^{[10
]}

Vizza, Carmine D. ^{[10
]}

Lang, Irene M. ^{[11
]}

Meier, Christian ^{[12
]}

Gruenig, Ekkehard ^{[13
]}

机构：

[1] Ohio State Univ Wexner Med Ctr, Dept Med, Columbus, OH 43210 USA

[2] McGill Univ, Jewish Gen Hosp, Ctr Pulm Vasc Dis, Div Cardiol, Montreal, PQ, Canada

[3] Vanderbilt Univ Sch Med, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN USA

[4] Vrije Univ Amsterdam Med Ctr, Pulm Dis, Amsterdam, Netherlands

[5] Cologne Univ Heart Ctr, Dept Cardiol, Cologne, Germany

[6] Univ Minnesota, Dept Med, Cardiovasc Div, Minneapolis, MN USA

[7] Johns Hopkins Univ, Pulm & Crit Care Med, Baltimore, MD USA

[8] Tufts Med Ctr, Pulm Crit Care & Sleep Med Div, Boston, MA USA

[9] Fdn IRCCS Policlin San Matteo, Div Cardiol, Pavia, Italy

[10] Sapienza Univ, Dept Cardiol, Rome, Italy

[11] Med Univ Vienna, Allgemeines Krankenhaus, Dept Internal Medicine 2, Div Cardiol, Vienna, Austria

[12] Global Med Affairs, Bayer AG, Berlin, Germany

[13] Heidelberg Univ Hosp, Ctr Pulm Hypertens, Thoraxklin Heidelberg gGmbH, Heidelberg, Germany

来源：

EUROPEAN RESPIRATORY REVIEW | 2022年 / 31卷 / 166期

关键词：

SOLUBLE GUANYLATE-CYCLASE; ENDOTHELIN-RECEPTOR ANTAGONIST; RIGHT HEART; EXERCISE CAPACITY; BOSENTAN TREATMENT; PROGNOSTIC VALUE; SILDENAFIL; PARAMETERS; MANAGEMENT; SURVIVAL;

D O I：

10.1183/16000617.0061-2022

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are progressive diseases that can lead to right heart failure and death. Right ventricular dysfunction, hypertrophy and maladaptive remodelling are consequences of increased right ventricular (RV) afterload in PAH and CTEPH and are indicative of long-term outcomes. Because RV failure is the main cause of morbidity and mortality in PAH and CTEPH, successful treatments should lead to improvements in RV parameters. Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of PAH and inoperable or persistent/recurrent CTEPH after pulmonary endarterectomy. This review examines the current evidence showing the effect of riociguat on the right ventricle, with particular focus on remodelling, function and structural parameters in preclinical models and patients with PAH or CTEPH.

引用

页数：12

共 50 条

[41] Pulmonary arterial hypertension due to antiphospholipid syndrome initially mimicking chronic thromboembolic pulmonary hypertension
Yeo, Jina
Shin, Nami
Ahn, Kyung-Jin
Seo, Miryoung
Jang, Albert Youngwoo
Kim, Minsu
Chung, Wook-Jin
CLINICAL HYPERTENSION, 2022, 28 (01)
[42] Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension
Lang, Irene
Meyer, Bernhard C.
Ogo, Takeshi
Matsubara, Hiromi
Kurzyna, Marcin
Ghofrani, Hossein-Ardeschir
Mayer, Eckhard
Brenot, Philippe
EUROPEAN RESPIRATORY REVIEW, 2017, 26 (143)
[43] Pulmonary endarterectomy in severe chronic thromboembolic pulmonary hypertension
de Perrot, Marc
Thenganatt, John
McRae, Karen
Moric, Jakov
Mercier, Olaf
Pierre, Andrew
Mak, Susanna
Granton, John
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2015, 34 (03) : 369 - 375
[44] Outpatient specialist clinics for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the Nordic countries
Kjellstrom, Barbro
Ryftenius, Henrik
Landenfelt-Gestre, Lise-Lotte
Ivarsson, Bodil
PULMONARY CIRCULATION, 2020, 10 (04)
[45] Chronic thromboembolic pulmonary hypertension
Scholzel, B. E.
Snijder, R. J.
Mager, J. J.
van Es, Hw.
Plokker, H. W. M.
Reesink, H. J.
Morshuis, W. J.
Post, M. C.
NETHERLANDS HEART JOURNAL, 2014, 22 (12) : 533 - 541
[46] Right ventricular adaptation to pressure-overload: Differences between chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension
Braams, Natalia J.
van Leeuwen, Joost W.
Noordegraaf, Anton Vonk
Nossent, Esther J.
Ruigrok, Dieuwertje
Marcus, J. Tim
Bogaard, Harm Jan
Meijboom, Lilian J.
de Man, Frances S.
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2021, 40 (06) : 458 - 466
[47] Riociguat for the treatment of pulmonary hypertension
Schermuly, Ralph T.
Janssen, Wiebke
Weissmann, Norbert
Stasch, Johannes-Peter
Grimminger, Friedrich
Ghofrani, Hossein Ardeschir
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (04) : 567 - 576
[48] Riociguat for the treatment of pulmonary hypertension
Hambly, Nathan
Granton, John
EXPERT REVIEW OF RESPIRATORY MEDICINE, 2015, 9 (06) : 679 - 695
[49] Riociguat for the treatment of pulmonary hypertension
Meis, Tobias
Behr, Juergen
EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (16) : 2419 - 2427
[50] Chronic thromboembolic pulmonary hypertension
O'Connell, Caroline
Montani, David
Savale, Laurent
Sitbon, Olivier
Parent, Florence
Seferian, Andrei
Bulifon, Sophie
Fadel, Elie
Mercier, Olaf
Mussot, Sacha
Fabre, Dominique
Dartevelle, Philippe
Humbert, Marc
Simonneau, Gerald
Jais, Xavier
PRESSE MEDICALE, 2015, 44 (12): : E409 - E416

← 1 2 3 4 5 →